Literature DB >> 22330935

Revisiting the pathologic finding of diffuse alveolar damage after lung transplantation.

Masaaki Sato1, David M Hwang, Kaori Ohmori-Matsuda, Cecilia Chaparro, Thomas K Waddell, Lianne G Singer, Michael A Hutcheon, Shaf Keshavjee.   

Abstract

BACKGROUND: Diffuse alveolar damage (DAD) is a non-specific pathologic diagnosis frequently encountered after lung transplantation. We examined the relationship between DAD and different forms of chronic lung allograft dysfunction (CLAD).
METHODS: We reviewed the results of 4,085 transbronchial biopsies obtained from 720 lung transplant recipients. DAD detected in biopsies within 3 months and newly detected DAD after 3 months were defined as early DAD and late new-onset DAD, respectively. Among patients with CLAD (FEV(1) <80% baseline), restrictive allograft syndrome (RAS) was defined by a decline in total lung capacity to <90% baseline and bronchiolitis obliterans syndrome (BOS) as CLAD without restrictive allograft syndrome (RAS). Kaplan-Meier analyses and multivariate proportional hazard models were used.
RESULTS: DAD was observed in 320 of 720 (44.4%) patients at least once; early and late new-onset DAD were observed in 264 of 707 (37.3%) and 87 of 655 (13.3%) patients, respectively. Early DAD was associated with significantly higher 90-day mortality (20 of 264 [7.6%] vs 11 of 443 [2.5%]; p = 0.001). Moreover, among 502 bilateral lung transplant recipients who had sufficient pulmonary function tests to distinguish BOS and RAS, early DAD was associated with earlier BOS onset (hazard ratio [HR] 1.24; confidence interval [CI] 1.04 to 1.47; p = 0.017; median time of BOS onset: 2,902 vs 4,005 days). Conversely, treated as a time-varying covariate, late new-onset DAD was a significant risk factor for RAS in a Cox model (HR 36.8; CI 18.3 to 74.1; p < 0.0001).
CONCLUSIONS: Early DAD is associated with early mortality and BOS, and late new-onset DAD increases the risk of RAS. Copyright Â
© 2012 International Society for Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22330935     DOI: 10.1016/j.healun.2011.12.015

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN: 1053-2498            Impact factor:   10.247


  20 in total

1.  Telomere length in patients with pulmonary fibrosis associated with chronic lung allograft dysfunction and post-lung transplantation survival.

Authors:  Chad A Newton; Julia Kozlitina; Jefferson R Lines; Vaidehi Kaza; Fernando Torres; Christine Kim Garcia
Journal:  J Heart Lung Transplant       Date:  2017-02-04       Impact factor: 10.247

Review 2.  [Fibrotic remodeling of the lung following lung and stem-cell transplantation].

Authors:  Christopher Werlein; Max Ackermann; Thia Leandra Hoffmann; Florian Laenger; Danny Jonigk
Journal:  Pathologe       Date:  2021-01-08       Impact factor: 1.011

3.  Validation and Refinement of Chronic Lung Allograft Dysfunction Phenotypes in Bilateral and Single Lung Recipients.

Authors:  Ariss DerHovanessian; Jamie L Todd; Alice Zhang; Ning Li; Aradhna Mayalall; C Ashley Finlen Copeland; Michael Shino; Elizabeth N Pavlisko; W Dean Wallace; Aric Gregson; David J Ross; Rajan Saggar; Joseph P Lynch; John Belperio; Laurie D Snyder; Scott M Palmer; S Sam Weigt
Journal:  Ann Am Thorac Soc       Date:  2016-05

4.  Outcome of unexplained acute respiratory distress syndrome with diffuse alveolar damage after lung transplantation.

Authors:  François Stéphan; Vincent Thomas de Montpréville; Coumba Diarra; Catherine Pilorge; Elie Fadel; Maria-Rosa Ghigna
Journal:  Intensive Care Med       Date:  2018-01-20       Impact factor: 17.440

5.  The histomorphological spectrum of restrictive chronic lung allograft dysfunction and implications for prognosis.

Authors:  Jan H von der Thüsen; Elly Vandermeulen; Robin Vos; Birgit Weynand; Erik K Verbeken; Stijn E Verleden
Journal:  Mod Pathol       Date:  2018-01-12       Impact factor: 7.842

6.  CXCR3 ligands are associated with the continuum of diffuse alveolar damage to chronic lung allograft dysfunction.

Authors:  Michael Y Shino; S Samuel Weigt; Ning Li; Vyacheslav Palchevskiy; Ariss Derhovanessian; Rajan Saggar; David M Sayah; Aric L Gregson; Michael C Fishbein; Abbas Ardehali; David J Ross; Joseph P Lynch; Robert M Elashoff; John A Belperio
Journal:  Am J Respir Crit Care Med       Date:  2013-11-01       Impact factor: 21.405

Review 7.  Chronic lung allograft dysfunction after lung transplantation: the moving target.

Authors:  Masaaki Sato
Journal:  Gen Thorac Cardiovasc Surg       Date:  2012-11-10

8.  Correlation between BAL CXCR3 chemokines and lung allograft histopathologies: A multicenter study.

Authors:  Michael Y Shino; Ning Li; Jamie L Todd; Megan L Neely; Jerry Kirchner; Heather Kopetskie; Michelle L Sever; Courtney W Frankel; Laurie D Snyder; Elizabeth N Pavlisko; Tereza Martinu; Lianne G Singer; Wayne Tsuang; Marie Budev; Pali D Shah; John M Reynolds; Nikki Williams; Mark A Robien; Scott M Palmer; Stephen Sam Weigt; John A Belperio
Journal:  Am J Transplant       Date:  2021-06-16       Impact factor: 9.369

9.  Generation of Lung Epithelium from Pluripotent Stem Cells.

Authors:  Amy P Wong; Janet Rossant
Journal:  Curr Pathobiol Rep       Date:  2013-04-03

10.  Impact of Allograft Injury Time of Onset on the Development of Chronic Lung Allograft Dysfunction After Lung Transplantation.

Authors:  M Y Shino; S S Weigt; N Li; A Derhovanessian; D M Sayah; R H Huynh; R Saggar; A L Gregson; A Ardehali; D J Ross; J P Lynch; R M Elashoff; J A Belperio
Journal:  Am J Transplant       Date:  2016-10-31       Impact factor: 9.369

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.